Compass Therapeutics’ recent findings on tovecimig, a bispecific antibody targeting DLL4 and VEGF-A, reveal a significant enhancement in median progression-free survival (PFS) when combined with paclitaxel for patients with unresectable advanced biliary tract cancer (BTC). The COMPANION-002 study demonstrated a median PFS of **4.7 months for the combination therapy compared to 2.6 months for paclitaxel alone, indicating a 56% reduction in the risk of progression (hazard ratio=0.44, p<0.0001). This improvement underscores the potential of tovecimig to address a critical unmet need in this patient population, which typically has limited treatment options.**

Despite the promising PFS results, overall survival (OS) analyses were complicated by a 54% crossover rate from the control arm, which led to confounding results. Crossover patients exhibited a median OS of 12.8 months, significantly higher than the 6.1 months observed in non-crossover patients. Overall, 85% of participants received tovecimig, yielding a pooled median OS of 8.9 months across the study cohort, which is notably longer than the typical 6-month benchmark for existing therapies in this setting. These findings highlight the potential clinical impact of tovecimig in improving outcomes for patients with BTC who lack actionable mutations.

The implications of these results are substantial for future research and drug development. The clear efficacy of tovecimig in combination with paclitaxel could shift current treatment paradigms for BTC, paving the way for new therapeutic strategies that leverage bispecific antibodies. Compass Therapeutics plans to engage with the FDA regarding a Biologics License Application (BLA), potentially accelerating the availability of this innovative therapy to the cholangiocarcinoma community and enhancing the therapeutic landscape for patients facing this aggressive cancer type.

Source: globenewswire.com